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I: Ocular Surface Squamous Neoplasia
Ocular surface squamous neoplasia (OSSN) includes a range of disease from mild dysplasia 
to carcinoma in situ and invasive squamous cell carcinoma. Affected sites include the 
conjunctiva, limbus, and cornea. Terminology varies and designations of invasive, pre-
invasive and benign OSSN have been proposed.1 Clinically, OSSN may present as an 
elevated mass or irritation with blood vessel tufts.1 The appearance may be gelatinous, 
papillomatous or leukoplakic.1,2 Location is most frequently the interpalpebral nasal limbus.
3,4
Epidemiology
The incidence of OSSN varies by geographic region. A 2013 meta-analysis determined the 
incidence of squamous cell carcinoma of the conjunctiva and cornea using data from the 
International Agency for Research on Cancer. Despite limitations to the surveillance data, 
the authors estimated the global age-standardized incidence of ocular squamous cell 
carcinoma of 0.18 cases per year per 100,000 males, and 0.08 cases per year per 100,000 
females. However, in Africa, the annual incidence was far greater, estimated to be 1.38 cases 
per 100,000 males and 1.18 cases/100,000 females. After Africa, incidence was greatest in 
Central and South America, followed by Oceania, North America, Asia, and lowest in 
Europe, with 0.05 and 0.01 cases per year per 100,000 males and females respectively.5 In a 
retrospective study of veterans in Florida, the prevalence of OSSN was 0.1%.6 Ethnicity may 
play a role as well, as a study in the United States identified Hispanic race as a risk factor 
but did not control for secondary factors such as geographic location or occupational sun 
exposure.7
Risk factors for OSSN include ultraviolet (UV) radiation exposure; immunocompromising 
conditions, in particular human immunodeficiency virus (HIV) infection; and HPV 
infection. The role of HPV will be discussed later. Presence of pterygium has also been 
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associated with OSSN.6 Some studies have shown associations of OSSN with sun exposure.
8
 In a case-control study of 318 cases of ocular surface carcinoma in situ and squamous cell 
carcinoma in Uganda, direct sun exposure of two hours or greater per day was a statistically 
significant risk factor.9 An Australian case control study found a strong association between 
skin cancer diagnosed before age 50 and development of OSSN.10 Other statistically 
significant risk factors included a history of solar keratoses, significant sun exposure as a 
young child (measured as spending >50% of time outdoors prior to age 6), and proximity to 
the equator (measured as cumulative time spent within 30 degrees of the equator).10,11
Because HIV infection and acquired immunodeficiency syndrome (AIDS) have been 
associated with increased incidence of both AIDS-defining cancers and other malignancies,
12,13
 HIV has been extensively studied as a risk factor for the development of OSSN. HIV 
infection has been associated with increased incidence of OSSN in multiple studies.
12,14-1718-22
 HIV-infected individuals develop OSSN at a younger age and present at a more 
advanced stage compared to those without HIV.23-25 The incidence of OSSN in HIV positive 
individuals correlates inversely with CD4+ T cell count, leading some investigators to 
hypothesize that antiretroviral therapy may decrease the risk of OSSN.26 The role of 
immunologic dysfunction in the development of OSSN in supported by the observation that 
immunosuppression due to organ transplantation also increases the risk of OSSN.27
Classification
OSSN is classified as benign, pre-invasive and invasive. The benign category includes 
papillomas, benign hereditary intraepithelial dyskeratosis and pseudoepitheliomatous 
hyperplasia. Neoplastic lesions that remain intraepithelial are defined as pre-invasive. There 
are three grades of pre-invasive OSSN. Grades I, II and III dysplasia correspond to 
dysplastic cells located in the outer, outer and middle, and entire epithelial layer, 
respectively. Grade III pre-invasive OSSN is synonymous with carcinoma in situ. Invasive 
OSSN is characterized by dysplastic cells extending beyond the epithelium past Bowman's 
layer and into the stroma.1
Pathogenesis
The pathogenesis of OSSN is an area of active inquiry, as a better understanding of the 
mechanism of disease may lead to improved methods of prevention and treatment. Proposed 
theories of carcinogenesis include dysregulation of limbal stem cells and alterations in 
transcription factor activation due to phosphorylation of receptor sites for cytokines and 
growth factors.28 Ultraviolet light, specifically UVB radiation (290-320 nm wavelength), 
may damage DNA by forming dimers through crosslinking, resulting in disruption of DNA 
polymerase function.29 Furthermore, ultraviolet radiation exposure may contribute to 
reactivation of HPV infection.4
Mutation of p53, with resultant dysregulation of tumor suppression, has been identified in a 
portion of OSSN cases.30 HPV may contribute to OSSN pathogenesis is through the 
formation of a protein complex between the HPV E6 protein and the host p53 protein 
product, which results in inhibition of the p53 tumor suppressor action.31
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UV radiation induces mutagenesis through base dimer formation,29 and may induce 
transcription of HPV proteins E6 and E7. In cells that harbor latent HPV infection these 
proteins may lead to formation of potentially premalignant papillomas.32
Treatment
Surgery has historically been the mainstay of treatment. In a case series of 397 cases of 
corneal or conjunctival squamous cell carcinoma (SCC) or conjunctival intraepithelial 
neoplasia (CIN) in Uganda, a standardized surgical excision with 3mm margins or excision 
to the limbus of conjunctival lesions and shallow keratectomy or epithelial sharp dissection 
for lesions involving the cornea resulted in a recurrence rate of 3.2% over a median 32-
month follow-up period.3 Other reported rates of recurrence have been significantly higher, 
with 5% recurrence with margins clear of tumor and 53% recurrence with dysplastic or 
tumor cells present at the surgical margin.2 Cryotherapy has been employed simultaneously 
with surgery.33
In addition, topical chemotherapy has also been used, both for debulking prior to surgical 
excision34 and as an adjuvant to surgery. In a case series of thirteen immunocompromised 
patients with ocular squamous cell carcinoma, interferon alpha-2b and mitomycin C were 
used in combination with surgery. The patients in this study who received interferon 
alpha-2b and surgical excision did well with no recurrence of tumor.24 However, only five 
patients received this treatment and follow-up was limited to a mean of ten months.
Nonsurgical therapy of OSSN with interferon alpha-2b has shown promise with a recent 
study demonstrating no statistical difference in recurrence rates between patients treated 
with interferon therapy and surgical excision.33 The rate of tumor resolution through 
treatment of carcinoma in situ with interferon alpha-2b has been as high as 92%.35 
Interferon alpha-2b is a chemotherapeutic agent with uses in other cancer treatment 
regimens such as renal cell carcinoma.33 Interferon alpha-2b has been applied via topical 
eye drops, subconjunctival injection, or both.33 Potential benefits of topical therapy include 
avoidance of surgery and a theoretical decrease in the risk of symblepharon formation. 
However, no symblepharon formation occurred in either surgical or medical intervention 
groups in a 2014 case review comparing surgical and medical therapy.33 Side effects of 
discomfort, conjunctivitis and irritation, and corneal epithelial defects have been reported.33 
The presence of HPV did not affect the rate of treatment failure of interferon alpha-2b in 
OSSN.36
No high-quality clinical trials of OSSN treatment in HIV-infected patients have been 
performed, therefore more research is needed to determine efficacy.37
Outcomes of OSSN
With therapy, the prognosis for OSSN is good. The rate of metastasis is <2%, with a 5% 
local recurrence rate.38 Untreated OSSN can result in extension into the globe, orbit, or 
distant metastasis.25 Management of larger tumors includes enucleation, for tumors 
extending into the eye, and exenteration, for those invading the orbit.25 In a case-control 
study of 200 patients, the tumor was more likely to present as Stage IV (defined as invasion 
of the orbit) or to recur in patients with HIV than in immunocompetent patients.25 In 
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immunocompromised patients, death has been reported as a result of aggressive recurrence 
with squamous cell carcinoma invasion of the brain.38 For patients with HIV, antiretroviral 
therapy is likely to be beneficial, as evidenced by a case report of a patient with biopsy-
proven squamous cell carcinoma of the conjunctiva with orbital invasion in whom total 
regression and resolution of the tumor occurred following antiretroviral therapy alone.39
II. Human Papillomaviruses
As noted above, HPV has been implicated in the pathogenesis of OSSN. Papillomaviruses 
cause infection in a wide range of vertebrate species, but they are species-specific. 
Papillomaviruses are nonenveloped, with an icosahedral capsid enclosing a double-stranded 
DNA genome.40 HPVs are typed based on genotypic homology of the genome segment 
encoding the major capsid protein. There are at least 184 known HPV types.41
Common benign manifestations of HPVs include common warts, anogenital warts, recurrent 
respiratory papillomatosis, and oral squamous cell papillomas. HPV types can be grouped 
by propensity to cause infection at either cutaneous (e.g., common warts) or mucosal sites 
(e.g., anogenital warts). Mucosal types can be further divided into those associated with high 
or low risk of malignant transformation. The prototypical HPV-associated malignancy is 
cervical carcinoma;42 HPV types 16 and 18 account for 71% of invasive cervical cancer 
lesions worldwide.43 Additional high-risk HPV types include 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59, 66, 67, 68, 73, and 82.41
The causal link between HPV and cervical carcinoma was established via several lines of 
evidence. Cervical carcinoma was observed to be less common in Catholic nuns;44 
conversely, a positive association has been noted between number of lifetime sexual partners 
and risk of cervical cancer.45 These and similar observations suggested a sexually 
transmitted risk factor for cervical cancer. In one meta-analysis, infection with high-risk 
HPV types was associated with a relative risk for cervical squamous cell carcinoma of 189 
(95% confidence interval: 133-267).45 The magnitude of this risk far exceeds other putative 
risk factors. Prospective studies have found that persistent infection with high-risk HPV 
types is the primary risk factor for the development of cervical intraepithelial neoplasia.46 
Finally, receipt of HPV vaccination has been associated with a decreased risk of cervical 
cellular atypia and cervical intraepithelial neoplasia.47
In addition to epidemiologic studies, the biology of high-risk HPV types supports their 
oncogenic potential. The viral proteins E6 and E7 act cooperatively by numerous 
mechanisms to promote integration of foreign DNA into the cellular genome and 
immortalize human cells, and these proteins are consistently expressed in lesions.48 
Furthermore, xenografts of human foreskin infected with HPV type 16 develop 
intraepithelial neoplasia in severe combined immunodeficiency mice.49
Taken together, these data strongly suggest a causal role of high-risk HPV types in cervical 
cancer. In addition, oncogenic HPV types have been convincingly implicated in 
oropharyngeal,50 anal,51,52 vulvar,52 vaginal,52 and penile cancers.53 Relationships between 
HPV and esophageal squamous cell carcinoma,54 sinonasal carcinoma,55 lung cancer,56 and 
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breast cancer,57,58 have been posited, but the role of HPV remains controversial. The 
putative role of HPV in the pathogenesis of ocular squamous surface neoplasia is discussed 
below.
III: Role of HPV in OSSN
The mechanism by which HPV infection may lead to the development of dysplasia and 
carcinoma is under investigation. HPV is present in some cases of OSSN, but not all, and is 
likewise present in a portion of normal tissue biopsies in many studies. HPV is not necessary 
or sufficient to cause OSSN, but may contribute to tumorigenesis.
A 2013 meta-analysis demonstrated that the relative risk of OSSN is increased with the 
presence of HIV and cutaneous HPV subtypes. Of sixteen studies identified that address 
mucosal HPV and OSSN, only five studies addressed both cutaneous and mucosal HPV 
subtypes in association with OSSN. In those five studies, there was no significant risk 
associated with mucosal HPV subtype infection and OSSN.16
A meta-analysis of the prevalence of HPV in pterygia and OSSN estimated prevalence of 
18.6% in pterygia and 33.8% in OSSN. 59 This review was limited by the variation in 
methodology across the studies, the lack of controls in some studies, and the inconsistent 
definition of the study population. Among these reports, HPV prevalence ranged from 0 to 
100% for both pterygia and OSSN, suggesting a high risk of bias within the source 
literature.59 A table summarizing the original literature, which consists of case-control 
studies and case series, is shown in Table I.
Of the thirty-four studies reviewed, HPV was detected in at least one case of OSSN in 27 
studies (79%). Comparison across studies is limited due to differences in viral detection 
methods, which likely results in highly variable sensitivity. Methods of detection of HPV 
included polymerase chain reaction (PCR) with various primers specific for broad reading 
frames present in all strains of HPV, or with primers specific to fewer HPV strains, or 
immunohistochemistry with enzyme-linked immunosorbent assay (ELISA). The tissue 
tested was frequently paraffin embedded or frozen, although one study employed 
conjunctival swabs of living tissue. Positive and negative controls were variably employed in 
these studies.
IV. Vaccination for Human Papillomaviruses
In 1992, Kirnbauer et al. discovered that the major capsid protein of HPV, L1, assembled 
itself into a particle closely resembling the intact virion and that this virus-like particle 
(VLP) induced neutralizing antibody responses in rabbits.90 After these findings were 
confirmed in other mammals, a human study found that HPV-11 VLP induced high specific 
antibody titers in women, and the sera of women with high-titer responses neutralized 
HPV-11.91 A Phase II trial of HPV-16 VLP confirmed immunogenicity and safety with and 
without an adjuvant.92 This was followed by a randomized controlled trial demonstrating 
100 percent efficacy by vaccination with HPV-16 VLP in preventing persistent HPV-16 
infection.93
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Subsequent clinical trials demonstrated the efficacy of a bivalent vaccine containing HPV 
types 16 and 1894 and a quadrivalent vaccine containing HPV types 6, 11, 16, and 18.95 The 
quadrivalent vaccine, developed by Merck and marketed as Gardasil, was approved by the 
Food and Drug Administration (FDA) in 2006 for use in females between 9 and 26 years of 
age.96 The bivalent vaccine, developed by GlaxoSmithKline and marketed as Cervarix, was 
approved by the FDA in 2009 for use in females aged 10 through 25 years of age.97 
Cervarix) for use in females and updated HPV vaccination recommendations from the 
Advisory Committee on Immunization Practices (ACIP) Both vaccines are administered on 
a three-dose schedule, with the second dose given 1-2 months after the first and the third 
dose given 6 months after the first. The Advisory Committee on Immunization Practices 
(ACIP) of the Centers for Disease Control and Prevention (CDC) recommended vaccination 
of girls aged 11 or 12 years with catch-up vaccination recommended up to age 26; no 
preference was expressed for either product.97
A randomized trial of boys and men between 16 and 26 years of age demonstrated efficacy 
of quadrivalent vaccine in the prevention of genital infection with HPV types 6, 11, 16, and 
18.98 In 2009, quadrivalent HPV vaccine was licensed by the FDA for use in males. The 
ACIP subsequently recommended routine vaccination of males aged 11 or 12 years with 
catch-up vaccination recommended between ages 13 and 21 and an option between ages 22 
and 26.99
A 9-valent HPV vaccine, adding types 31, 33, 45, 52, and 58 to the quadrivalent vaccine, 
was demonstrated to have efficacy of 96.7% in protecting against the newly added types and 
generated antibody responses equivalent to those generated by quadrivalent vaccine against 
types 6, 11, 16, and 18.100 The 9-valent vaccine, developed by Merck and marketed as 
Gardasil 9, was approved by the FDA in 2014.101 The ACIP recommended routine 
vaccination of both males and females at age 11 or 12 years and catch-up vaccination of 
females through age 26 years and males through age 21 years. Females can be vaccinated 
with either of the three available vaccines, while it is recommended that males receive either 
quadrivalent or 9-valent vaccine. In addition, it is recommended that immunocompromised 
persons and men who have sex with men receive either quadrivalent or 9-valent vaccine up 
through age 26 years.101
All three approved HPV vaccines are generally safe. Injection-site pain, redness, and 
swelling are common for all three vaccines, as are low-grade fever and headache.96,97,101 
Syncope following vaccination has been described for the bivalent and quadrivalent 
vaccines.97,102 No other adverse events have been reported to occur at rates above the 
expected baseline.102,103
Follow-up studies of bivalent HPV vaccine and of quadrivalent HPV vaccine have 
demonstrated persistent seropositivity and vaccine effectiveness after 9 years104 and 8 years,
105
 respectively. Further inquiries into the duration of protection are ongoing.
Several ecological studies of the public-health effect of HPV vaccination programs have 
been conducted. National studies have demonstrated declines in detection of targeted HPV 
vaccine strains from cervical samples106,107 and in diagnosis of HPV-related benign genital 
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lesions.108-110 An ecological study in Australia found that, during the three years following 
introduction of quadrivalent HPV vaccination, the incidence of high-grade cervical 
abnormalities declined in females less than 18 years of age but not in older females.111
In addition to these ecological studies, receipt of HPV vaccination has also been linked to 
decreased risk of cervical dysplasia.47,112113 A systematic evidence review concluded that 
the incidence of infections due to vaccine-strain HPV, incidence of anogenital warts, and 
incidence of cervical dysplasia were declining and that the decline was likely due to HPV 
vaccination programs.114 No evidence is yet available about the effect of HPV vaccination 
on the incidence of cervical cancer or other HPV-related cancers.
V: Potential Role of HPV vaccine in OSSN
The commercially available HPV vaccines discussed above provide protection against many 
of the HPV strains associated with OSSN. Although not all associated strains are targeted by 
the vaccines, a degree of cross-protection against HPV strains not specifically targeted by 
the available vaccines has been demonstrated with the bivalent vaccine for subtypes 31, 33, 
45, and 51.115-117 The quadrivalent vaccine has also shown cross-protection for HPV 
subtypes 31, 33, and 45,116,117 however, the bivalent vaccine has shown higher cross-
protective efficacy for HPV-31 and HPV-45.117
Of the strains of HPV covered by the 9-valent vaccine, eight of the nine strains have been 
associated with OSSN. HPV-58 is the only vaccine strain not associated with OSSN. 
Additional strains of HPV identified in association with OSSN, but not targeted by the HPV 
vaccine include HPV-1, 5, 8, 12, 14, 17, 19, 23, 24, 35, 36, 37, 38, 44, 51, 66, 80, 100, 
RTRX7, DL-473, PPHLIFRC, and CJ198. Not all of these strains have been shown to be 
oncogenic, as such their presence may or may not contribute to the pathogenesis of OSSN. 
Additionally, the degree of cross-protection from immunization against these strains, if 
present, is unknown.
Efficacy of HPV vaccines is highest when immunization occurs prior to viral exposure, thus 
prior to sexual debut.115 The U.S. Food and Drug Administration (FDA) approved HPV 
vaccinations for prevention of cancers of non-ocular organs discussed previously, what affect 
vaccination against the virus has on OSSN is unknown at this time. The association between 
HPV infection and OSSN has been repeatedly demonstrated, particularly with HPV 16, and 
many HPV strains identified in OSSN are targeted by the HPV 9-valent vaccine. Since the 
population that develops OSSN is considerably older than the currently vaccinated 
population and because the vaccine is relatively new, our knowledge of the potential effect 
of HPV on OSSN is limited. As the population of vaccinated persons continues to grow and 
age, the epidemiology of ocular surface disease may or may not respond.
VI: Conclusions
The role of HPV in the pathogenesis of OSSN has been debated for decades. The available 
literature, summarized above and in Table 1, suggests that HPV likely plays a role in a 
subset of OSSN cases. While there is a clear association between HPV and OSSN, with 
several suggested mechanisms by which the virus can initiate the cascade of tumorigenesis, 
Carroll et al. Page 7
Int Ophthalmol Clin. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
infection does not appear to be required for the development of OSSN. As carcinogenesis 
could conceivably result in the reactivation of latent virus, causation must be determined. 
The proportion of OSSN cases in which HPV plays a role is ill-defined. Even less is known 
about the natural history of ocular HPV infection. Studies of cervical HPV infection clearly 
established prolonged infection with an oncogenic genotype as the primary risk factor for 
cervical cancer. Analogous studies of HPV infection of the ocular surface have not been 
performed. It is clear that, to prevent cervical cancer due to a particular HPV genotype, 
vaccination against that type must occur prior to acquisition via sexual transmission. The 
timing and mechanism of ocular acquisition of HPV is not known. It does, however, seem 
unlikely that acquisition of most oncogenic genotypes, which are largely tropic to the 
genitourinary tract, would occur prior to the onset of sexual activity.
Therefore, it is possible that widespread vaccination against HPV may prevent future cases 
of OSSN. However, it is not known that HPV vaccination will precede ocular HPV 
acquisition, and the proportion of OSSN attributable to HPV is unknown. Given the rarity of 
the disease in immunocompetent individuals in the industrialized world, any potential 
benefit is perhaps most likely to be seen in the developing world and in 
immunocompromised patients. Before the effect of HPV vaccination campaigns on the 
incidence of OSSN can be estimated, the natural history of ocular HPV infection and the 
relationship between HPV and OSSN must be more clearly defined. Inversely, a decline in 
the incidence of OSSN in highly HPV-vaccinated populations, adjusted for changing 
epidemiology of immunocompromising conditions and availability of effective treatment for 
HIV, would strongly support the assertion that HPV has a causal role in OSSN, though such 
an effect is not likely to be seen for decades.
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